December 2020 Br J Cardiol 2020;27:141–2 doi:10.5837/bjc.2020.039
Jordan Faulkner, Francis A Kalu
Introduction Primary percutaneous coronary intervention (pPCI) and stenting are considered first-line management of ST-elevation myocardial infarction (STEMI).1 There is a well-recognised inflammatory component to ischaemic heart disease (IHD), and, thus, C-reactive protein (CRP) has been implicated as a poor prognostic indicator for stent re-stenosis, cardiovascular mortality and all-cause mortality post-myocardial infarction (MI).1,2 Case An 87-year-old man presented to Accident and Emergency (A&E) for “a one day history of severe neck/parietal headache on background of recent discharge from hospital with an MI”. Past medical histor
May 2020 Br J Cardiol 2020;27:64–6 doi:10.5837/bjc.2020.011
Yuen W Liao, James Redfern, John D Somauroo, Robert M Cooper
Introduction Hypertrophic cardiomyopathy (HCM) predominantly results from genetic variants that affect cardiac sarcomeres. The result is a heterogeneous condition characterised by ventricular hypertrophy that cannot be explained by increased afterload (i.e. arterial hypertension, aortic stenosis). Various hypothesised mechanisms were potentially responsible for a perceived increased risk of arrhythmia during exercise in patients with HCM: dynamic left ventricular outflow tract obstruction (LVOTO) increasing left ventricular pressure and strain; sympathetic vagal imbalance; microvascular ischaemia and metabolic acidosis.1 Subsequent internatio
November 2019 Br J Cardiol 2019;26:128–9
Ian Mason, BJC Staff
Professor D John Betteridge Professor John Betteridge With sadness, we report the death of Professor D John Betteridge, BSc, MB BS, PhD, MD, FRCP, FAHA, Consultant Physician, University College London Hospitals, London; Emeritus Professor of Endocrinology and Metabolism University College London; and Associate Dean, Royal Society of Medicine (RSM), who passed away on 4th October 2019, aged 71, following a long illness. John will be remembered with great fondness by his many colleagues and friends. He had a long and distinguished career – he was a BJC editorial board member, a past chair of HEART UK and past President of the Council on Lipid
August 2013 Br J Cardiol 2013;20:92-93 Online First
News from the world of cardiology
Details of two biomarker discovery programmes were presented by myself and other colleagues from Southampton.The early results were generated by our team, headed by Professor John Morgan, and build on several years of collaboration between cardiologists at the University Hospitals Southampton and scientists at the University of Southampton. The work hopes to advance sudden cardiac death risk stratification and ultimately move towards a more personal selection of interventions, such as implantable defibrillators. Traditional risk stratification markers, such as left ventricular function or QRS width, fail to identify those at greatest risk, or
August 2012 Br J Cardiol 2012;19:141–3 doi:10.5837/bjc.2012.027
Stephen Westaby, Ravi De Silva, Shane George, Duncan Young, Yaver Bashir
Case report Figure 1. The extracorporeal membrane oxygenation (ECMO) system A 20-year-old female student under investigation for syncopal attacks was found to have a normal electrocardiogram (ECG) and cardiac morphology on echocardiography. She then suffered ventricular fibrillation at rest while talking to friends. They performed cardiac massage and a paramedic ambulance arrived within four minutes. Defibrillation was attempted using anterior and lateral electrodes. When this was unsuccessful, she was intubated and a Lucas cardiac compression device applied, even though the Accident and Emergency (A&E) department was less than one mile a
March 2012 Br J Cardiol 2012;19:12–3
BJCardio Staff
NICE updates A new ‘Evidence Update’ has been produced by the National Institute for Health and Clinical Excellence (NICE), which summarises selected new evidence relevant to the NICE guideline on the management of chronic heart failure (CHF) in adults in primary and secondary care (clinical guideline 108).NICE says “Whilst Evidence Updates do not replace current accredited guidance, they do highlight new evidence that might generate a future changes in practice.” It says it will welcome feedback from societies and individuals in developing this service. The update is available from www.evidence.nhs.uk/evidence-update-2. New guides
July 2009 Br J Cardiol 2009;16:200
Mary N Sheppard
Editors: Capucci, A Piacenza, I Publisher: Informa HealthCare, 2006 ISBN: 9781841845784 Price: £80 The risk of sudden death after myocardial infarction is described particularly with regard to the era of early reperfusion/stent insertion. Pathophysiology is very well dealt with looking in detail at the substrate for arrhythmias, different types of arrhythmias and treatment of these, including ablation, drug therapy and implantable defibrillators. An interesting point made is that patients with implantable cardioverter defibrillators (ICDs) still die because the public erroneously think that ICDs will avoid the risk of sudden death and make
July 2002 Br J Cardiol 2002;9:406-10
Badri Chandrasekaran, Arvinder S Kurbaan
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits